WA
Consensus Narrative from 8 Analysts
VTAMA's Approval Will Open New Markets But May Impact Margins
Key Takeaways The acquisition of VTAMA and its potential approval could significantly expand Organon's market, driving revenue growth and improving net margins by 2026. NEXPLANON's growth and new biosimilars launches support sustained revenue growth and strategic enhancement of profit margins.
View narrativeUS$21.00
FV
27.2% undervalued intrinsic discount0.37%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
18 days ago author updated this narrative